RxSight (RXST) Stock Forecast & Price Target

Compare

240 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RXST Analyst Ratings

Hold

1 Buy

7 Hold

1 Sell

Based on 9 analysts giving stock ratings to

RxSight

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RXST Stock 12 Month Forecast

Average Price Target

$11.79

▲(48.30%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for RxSight in the last 3 months. The average price target is $11.79 with a high forecast of $22.00 and a low forecast of $9.00. The average price target represents a 48.30% change from the last price of $7.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","57":"$57","20.25":"$20.3","32.5":"$32.5","44.75":"$44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,20.25,32.5,44.75,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.12,13.803076923076922,14.486153846153845,15.169230769230769,15.852307692307692,16.535384615384615,17.21846153846154,17.90153846153846,18.584615384615383,19.267692307692307,19.950769230769232,20.633846153846154,21.316923076923075,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.12,13.017692307692307,12.915384615384614,12.813076923076922,12.71076923076923,12.608461538461537,12.506153846153845,12.403846153846153,12.301538461538462,12.199230769230768,12.096923076923076,11.994615384615384,11.892307692307691,{"y":11.79,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.12,12.803076923076922,12.486153846153845,12.169230769230769,11.852307692307692,11.535384615384615,11.218461538461538,10.901538461538461,10.584615384615384,10.267692307692307,9.95076923076923,9.633846153846154,9.316923076923077,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":56.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.39,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.15,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.87,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.22,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.98,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$22.00

Average Price Target$11.79

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$7.5

Hold

-5.66%

Downside

Reiterated

07/10/25

The overall stock score reflects a mix of strong revenue growth and customer satisfaction, offset by significant operational and profitability challenges. Bearish technical signals and a negative valuation picture further contribute to the lower score.

Young LiJefferies

Jefferies

$24→$9

Hold

13.21%

Upside

Downgraded

07/10/25

RxSight downgraded to Hold from Buy at JefferiesRxSight downgraded to Hold from Buy at Jefferies

Steven LichtmanOppenheimer

Oppenheimer

―

Hold

―

Downgraded

07/09/25

RxSight downgraded to Perform from Outperform at OppenheimerRxSight downgraded to Perform from Outperform at Oppenheimer

Adam MaederPiper Sandler

Piper Sandler

$18→$10

Hold

25.79%

Upside

Reiterated

07/09/25

RxSight price target lowered to $10 from $18 at Piper SandlerRxSight price target lowered to $10 from $18 at Piper Sandler

Larry BiegelsenWells Fargo

Wells Fargo

Hold

13.21%

Upside

Downgraded

07/09/25

Wells Fargo downgrades RxSight (RXST) to a Hold

Craig BijouBank of America Securities

Bank of America Securities

$18→$9

Sell

13.21%

Upside

Reiterated

07/09/25

Analysts Offer Insights on Healthcare Companies: RxSight (NASDAQ: RXST), Gain Therapeutics (NASDAQ: GANX) and Edwards Lifesciences (NYSE: EW)

David SaxonNeedham

Needham

$22

Buy

176.73%

Upside

Reiterated

07/09/25

RxSight's Strategic Initiatives and International Expansion Support Buy Rating Amidst Revenue Challenges

Thomas StephanStifel Nicolaus

Stifel Nicolaus

$17→$9

Hold

13.21%

Upside

Reiterated

07/09/25

RxSight price target lowered to $9 from $17 at StifelRxSight price target lowered to $9 from $17 at Stifel

Ryan ZimmermanBTIG

BTIG

―

Hold

―

Downgraded

07/09/25

RxSight downgraded to Neutral from Buy at BTIGRxSight downgraded to Neutral from Buy at BTIG

Lila ImplantraAI Firm

AI Firm

$15.5→$14.5

Hold

82.39%

Upside

Reiterated

06/12/25

Danielle AntalffyUBS

UBS

$45→$16

Hold

101.26%

Upside

Downgraded

04/09/25

RxSight's Market Challenges and Revised Growth Projections Lead to Hold Rating

Robbie MarcusJ.P. Morgan

J.P. Morgan

$40→$17

Sell

113.84%

Upside

Downgraded

04/03/25

RxSight downgraded to Underweight from Overweight at JPMorganRxSight downgraded to Underweight from Overweight at JPMorgan

Patrick WoodMorgan Stanley

Morgan Stanley

$42

Buy

428.30%

Upside

Reiterated

04/03/25

RxSight's Long-Term Growth Potential Justifies Buy Rating Despite Short-Term Challenges

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$7.5

Hold

-5.66%

Downside

Reiterated

07/10/25

Young LiJefferies

Jefferies

$24→$9

Hold

13.21%

Upside

Downgraded

07/10/25

RxSight downgraded to Hold from Buy at JefferiesRxSight downgraded to Hold from Buy at Jefferies

Steven LichtmanOppenheimer

Oppenheimer

―

Hold

―

Downgraded

07/09/25

RxSight downgraded to Perform from Outperform at OppenheimerRxSight downgraded to Perform from Outperform at Oppenheimer

Adam MaederPiper Sandler

Piper Sandler

$18→$10

Hold

25.79%

Upside

Reiterated

07/09/25

RxSight price target lowered to $10 from $18 at Piper SandlerRxSight price target lowered to $10 from $18 at Piper Sandler

Larry BiegelsenWells Fargo

Wells Fargo

Hold

13.21%

Upside

Downgraded

07/09/25

Wells Fargo downgrades RxSight (RXST) to a Hold

Craig BijouBank of America Securities

Bank of America Securities

$18→$9

Sell

13.21%

Upside

Reiterated

07/09/25

Analysts Offer Insights on Healthcare Companies: RxSight (NASDAQ: RXST), Gain Therapeutics (NASDAQ: GANX) and Edwards Lifesciences (NYSE: EW)

David SaxonNeedham

Needham

$22

Buy

176.73%

Upside

Reiterated

07/09/25

RxSight's Strategic Initiatives and International Expansion Support Buy Rating Amidst Revenue Challenges

Thomas StephanStifel Nicolaus

Stifel Nicolaus

$17→$9

Hold

13.21%

Upside

Reiterated

07/09/25

RxSight price target lowered to $9 from $17 at StifelRxSight price target lowered to $9 from $17 at Stifel

Ryan ZimmermanBTIG

BTIG

―

Hold

―

Downgraded

07/09/25

RxSight downgraded to Neutral from Buy at BTIGRxSight downgraded to Neutral from Buy at BTIG

Lila ImplantraAI Firm

AI Firm

$15.5→$14.5

Hold

82.39%

Upside

Reiterated

06/12/25

Danielle AntalffyUBS

UBS

$45→$16

Hold

101.26%

Upside

Downgraded

04/09/25

RxSight's Market Challenges and Revised Growth Projections Lead to Hold Rating

Robbie MarcusJ.P. Morgan

J.P. Morgan

$40→$17

Sell

113.84%

Upside

Downgraded

04/03/25

RxSight downgraded to Underweight from Overweight at JPMorganRxSight downgraded to Underweight from Overweight at JPMorgan

Patrick WoodMorgan Stanley

Morgan Stanley

$42

Buy

428.30%

Upside

Reiterated

04/03/25

RxSight's Long-Term Growth Potential Justifies Buy Rating Despite Short-Term Challenges

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering RxSight

1 Month

xxx

Success Rate

14/25 ratings generated profit

Average Return

+6.23%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.00% of your transactions generating a profit, with an average return of +6.23% per trade.

3 Months

xxx

Success Rate

12/25 ratings generated profit

Average Return

+8.10%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 48.00% of your transactions generating a profit, with an average return of +8.10% per trade.

1 Year

David SaxonNeedham

Success Rate

13/25 ratings generated profit

Average Return

+39.95%

reiterated a buy rating 2 days ago

Copying David Saxon's trades and holding each position for 1 Year would result in 52.00% of your transactions generating a profit, with an average return of +39.95% per trade.

2 Years

xxx

Success Rate

8/25 ratings generated profit

Average Return

+31.76%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 32.00% of your transactions generating a profit, with an average return of +31.76% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RXST Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RXST has received 5 Buy Ratings, 12 Hold Ratings, and 3 Sell Ratings. RXST average Analyst price target in the past 3 months is 11.79.

Each month's total comprises the sum of three months' worth of ratings.

RXST Financial Forecast

RXST Earnings Forecast

Next quarter’s earnings estimate for RXST is -$0.24 with a range of -$0.33 to -$0.15. The previous quarter’s EPS was -$0.20. RXST beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.07% of the time in the same period. In the last calendar year RXST has Preformed in-line its overall industry.

RXST Sales Forecast

Next quarter’s sales forecast for RXST is $35.19M with a range of $33.60M to $39.00M. The previous quarter’s sales results were $37.90M. RXST beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year RXST has Preformed in-line its overall industry.

RXST Stock Forecast FAQ

What is RXST’s average 12-month price target, according to analysts?

Based on analyst ratings, RxSight’s 12-month average price target is 11.79.

What is RXST’s upside potential, based on the analysts’ average price target?

RxSight has 48.30% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RXST a Buy, Sell or Hold?

RxSight has a consensus rating of Hold which is based on 1 buy ratings, 7 hold ratings and 1 sell ratings.

What is RxSight’s price target?

The average price target for RxSight is 11.79. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.00 ,the lowest forecast is $9.00. The average price target represents 48.30% Increase from the current price of $7.95.

What do analysts say about RxSight?

RxSight’s analyst rating consensus is a Hold. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of RXST?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

RxSight (RXST) Stock Forecast & Price Target

RXST Analyst Ratings

RXST Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering RxSight

RXST Analyst Recommendation Trends

RXST Financial Forecast

RXST Earnings Forecast

RXST Sales Forecast

RXST Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts